Skip to main content
eScholarship
Open Access Publications from the University of California

UCLA

UCLA Previously Published Works bannerUCLA

Decline in SARS-CoV-2 Antibodies After Mild Infection Among Frontline Health Care Personnel in a Multistate Hospital Network - 12 States, April-August 2020.

  • Author(s): Self, Wesley H;
  • Tenforde, Mark W;
  • Stubblefield, William B;
  • Feldstein, Leora R;
  • Steingrub, Jay S;
  • Shapiro, Nathan I;
  • Ginde, Adit A;
  • Prekker, Matthew E;
  • Brown, Samuel M;
  • Peltan, Ithan D;
  • Gong, Michelle N;
  • Aboodi, Michael S;
  • Khan, Akram;
  • Exline, Matthew C;
  • Files, D Clark;
  • Gibbs, Kevin W;
  • Lindsell, Christopher J;
  • Rice, Todd W;
  • Jones, Ian D;
  • Halasa, Natasha;
  • Talbot, H Keipp;
  • Grijalva, Carlos G;
  • Casey, Jonathan D;
  • Hager, David N;
  • Qadir, Nida;
  • Henning, Daniel J;
  • Coughlin, Melissa M;
  • Schiffer, Jarad;
  • Semenova, Vera;
  • Li, Han;
  • Thornburg, Natalie J;
  • Patel, Manish M;
  • CDC COVID-19 Response Team;
  • IVY Network
  • et al.
Abstract

Most persons infected with SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), develop virus-specific antibodies within several weeks, but antibody titers might decline over time. Understanding the timeline of antibody decline is important for interpreting SARS-CoV-2 serology results. Serum specimens were collected from a convenience sample of frontline health care personnel at 13 hospitals and tested for antibodies to SARS-CoV-2 during April 3-June 19, 2020, and again approximately 60 days later to assess this timeline. The percentage of participants who experienced seroreversion, defined as an antibody signal-to-threshold ratio >1.0 at baseline and <1.0 at the follow-up visit, was assessed. Overall, 194 (6.0%) of 3,248 participants had detectable antibodies to SARS-CoV-2 at baseline (1). Upon repeat testing approximately 60 days later (range = 50-91 days), 146 (93.6%) of 156 participants experienced a decline in antibody response indicated by a lower signal-to-threshold ratio at the follow-up visit, compared with the baseline visit, and 44 (28.2%) experienced seroreversion. Participants with higher initial antibody responses were more likely to have antibodies detected at the follow-up test than were those who had a lower initial antibody response. Whether decay in these antibodies increases risk for reinfection and disease remains unanswered. However, these results suggest that serology testing at a single time point is likely to underestimate the number of persons with previous SARS-CoV-2 infection, and a negative serologic test result might not reliably exclude prior infection.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
For improved accessibility of PDF content, download the file to your device.
Current View